Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

of RA patients. By blocking the CCR1 ligands including the super-activated forms from interacting with the CCR1 receptor, CCX354 is designed to reduce the migration of inflammatory cells leading to rheumatoid arthritis and subsequently joint destruction.

"CCX354 is the third product candidate to enter the clinic from our discovery platform and marks another important milestone for ChemoCentryx," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "ChemoCentryx has repeatedly shown that it can develop clearly differentiated product candidates by leveraging its technology platform and that it can also advance them expeditiously into clinical development. In less than a year, our product pipeline has expanded from a single ongoing clinical program to now three clinical assets in development."

"We are delighted that this CCR1 antagonist program with ChemoCentryx has progressed to the clinic," said Hugh Cowley, Senior Vice President of GSK's Center of Excellence for External Drug Discovery (CEEDD). "CCX354 may become a promising drug candidate against a number of potential inflammatory diseases and we look forward to seeing the data as it emerges from the clinical trial program."

ChemoCentryx and GSK's Center of Excellence for External Drug Discovery (CEEDD) entered into a multi-product strategic alliance in August 2006 for the discovery, development and commercialization of novel medicines targeting four defined chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. Under the terms of the agreement, ChemoCentryx is responsible for the discovery and development of up to six small molecule drug candidates across four targets through clinical proof-of-concept, at which point GSK will have exclusive options to license each product for further development and commercialization on a worldwide basis. CCX354 is the second compound under the GSK alliance to enter the clinic. ChemoCentryx's lead com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... March 27, 2015 Report Details  ... leading ophthalmic drug companies  What does the ... ophthalmic industry ? Visiongain,s brand new report shows you ... prospects there. Our 242-page report provides 185 ... in the industry and the future market prospects. Our ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Genetics, a global leader in genomic services, announced today ... Generation Sequencing System as well as received the first ... been an early adapter of Illumina systems since late ... Provider. A team of scientists routinely process libraries for ...
... 25 QBC Diagnostics was awarded one of the largest ... agreed to install QBC STAR hematology analyzers on surface ships ... a 9-parameter complete blood count through its patented dry hematology ... this technology, as well as the unit,s small footprint and ...
Cached Medicine Technology:Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities 2
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Designers ... a new overlay entitled Scratches 5K from Pixel Film ... scratch effects to any media inside Final Cut Pro ... “StoryBoard Corporate saves time and is an effective tool ... using FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/28/2015)... LTW Cyber is an innovation hub ... the purpose of addressing the needs of the global ... own opportunities to grow while seeking collaborative opportunities with ... , Ventures in LTW Cyber focus on secure application ... identifying vulnerabilities and analyzing open source. As the ...
(Date:3/27/2015)... Wellness for Cancer–the first organization to ... the spa and wellness industry–has certified Hands On to ... or are living with cancer. Hands On , ... will be identified with a special Wellness for Cancer ... safe, therapeutic services for cancer patients. , Wellness for ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with the ... for the 2015 and 2016 season. As the Storm’s exclusive ... athletic trainer for the team throughout each season. Tonight, the ... Cleveland Gladiators at Amalie Arena; the game starts at 7:30pm. ... as it gives us the opportunity, to provide health and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... among people who have mild memory loss, and they can ... largest ever investigation into heart disease and stroke in those ... some of who had a MRI scan which could indicate ... at Wake Forest University now report on this sub-group, observing ...
... been at a loss when it comes to health issues. ... tobacco smoke for residents. Environmental tobacco smoke// (ETS, or passive ... - from exacerbation of asthma to eye irritation and even ... workplace and in public places. Researchers at the University of ...
... new study, researchers found that the treatment naltrexone is ... abuse. Researchers of alcohol often distinguish two patterns of ... drinking are saved up for the weekend and holidays, ... regularly and often with meals. The Anglo-Saxon pattern has ...
... new study, children of people with mood disorders who have ... own lives as well. The link is especially strong among ... who suffer from mood disorders themselves. ,Research has shown ... risk of committing suicide, but few studies have looked at ...
... they have observed that postmenopausal women who use estrogen are ... tissue change in the joints that causes pain in that ... over 40 years old. Experts estimate up to 70 percent ... conducted a study to see if estrogen plays a role ...
... a clot-buster injection may unclog a mechanical heart pump, ... from University Hospital in Germany,// felt that this is ... heart failure patients who receive left ventricular assist devices. ... pump-like device that is surgically implanted to maintain the ...
Cached Medicine News:
Richardson Retractor...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
... The Advanta™ PTFE facial implant is ... intended for augmentation or repair of ... This product is available in sheets ... Advanta™ PTFE round facial implant strands ...
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an ...
Medicine Products: